FR3084584B1 - Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes - Google Patents

Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes Download PDF

Info

Publication number
FR3084584B1
FR3084584B1 FR1857267A FR1857267A FR3084584B1 FR 3084584 B1 FR3084584 B1 FR 3084584B1 FR 1857267 A FR1857267 A FR 1857267A FR 1857267 A FR1857267 A FR 1857267A FR 3084584 B1 FR3084584 B1 FR 3084584B1
Authority
FR
France
Prior art keywords
injection
amphiphilic compound
solution
human glucagon
hydrophobic radicals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1857267A
Other languages
English (en)
Other versions
FR3084584A1 (fr
Inventor
Emmanuel Dauty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to FR1857267A priority Critical patent/FR3084584B1/fr
Priority to PCT/EP2019/070953 priority patent/WO2020025825A1/fr
Publication of FR3084584A1 publication Critical patent/FR3084584A1/fr
Application granted granted Critical
Publication of FR3084584B1 publication Critical patent/FR3084584B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

[0001] L'invention concerne une composition stable physiquement sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : - du glucagon humain, et - un composé amphiphile comprenant un squelette hydrophile HB, substitué par au moins un radical hydrophobe -Hy de formule I.
FR1857267A 2018-08-03 2018-08-03 Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes Active FR3084584B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1857267A FR3084584B1 (fr) 2018-08-03 2018-08-03 Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
PCT/EP2019/070953 WO2020025825A1 (fr) 2018-08-03 2019-08-03 Solution injectable a ph 7 comprenant du glucagon humain, au moins une espece ionique et un compose amphiphile porteur de radicaux hydrophobes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1857267A FR3084584B1 (fr) 2018-08-03 2018-08-03 Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR1857267 2018-08-03

Publications (2)

Publication Number Publication Date
FR3084584A1 FR3084584A1 (fr) 2020-02-07
FR3084584B1 true FR3084584B1 (fr) 2020-11-06

Family

ID=65201005

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1857267A Active FR3084584B1 (fr) 2018-08-03 2018-08-03 Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes

Country Status (2)

Country Link
FR (1) FR3084584B1 (fr)
WO (1) WO2020025825A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091625A1 (fr) 2021-05-22 2022-11-23 Adocia Compositions comprenant des hormones à brève durée d'action pour traiter ou prévenir l'obésité et pompes comprenant ladite composition
EP4144362A1 (fr) 2021-09-06 2023-03-08 Adocia Compositions comprenant des hormones à brève durée d'action pour traiter ou prévenir l'obésité et pompes comprenant ladite composition
WO2022248419A2 (fr) 2021-05-22 2022-12-01 Adocia Compositions comprenant des hormones à action courte pour le traitement ou la prévention de l'obésité et pompes comprenant ladite composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
EP2417982A1 (fr) * 2010-07-30 2012-02-15 Ferring B.V. Stabilisation de gonadotrophines
CA3027238A1 (fr) * 2016-06-07 2017-12-14 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
US10559404B2 (en) * 2016-06-08 2020-02-11 Prysmian S.P.A. Traceable power cable and method

Also Published As

Publication number Publication date
WO2020025825A1 (fr) 2020-02-06
FR3084584A1 (fr) 2020-02-07

Similar Documents

Publication Publication Date Title
FR3084584B1 (fr) Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
JOP20200160A1 (ar) محاليل معلقة مائية للمركبات المسمى تي ام سي 278
BR112019017417A2 (pt) composições farmacêuticas de um derivado de um ácido biliar e microbioma e usos das mesmas
EP4252848A3 (fr) Oxystérols et leurs procédés d'utilisation
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
WO2020113213A3 (fr) Dérivés de pantéthéine cyclique et utilisations de ceux-ci
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
MY150091A (en) Prevention of hiv-infection
AU2020231934A8 (en) Compounds useful in HIV therapy
ATE454905T1 (de) Stabile injizierbare diclofenac- zubereitungen
NO20060896L (no) Alfa-aminoamidderivater nyttige som antiinflammatoriske midler
EA202091533A1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
EA202092069A1 (ru) Композиции и способы лечения макулярной дистрофии
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
CR20230164A (es) Compuestos fosfolípidos y usos de estos
ATE548043T1 (de) Polymorphe von 3-o-(3',3'- dimethylsuccinyl)betulinsäure-di-n-methyl-d- glucamin
CY1124270T1 (el) Οφθαλμικες συνθεσεις που περιλαμβανουν βιλαστινη, μια β-κυκλοδεξτρινη και τουλαχιστον ενα πηκτικο μεσο
WO2020121123A3 (fr) Analogues de nucléoside cyclopentyle utilisés comme antiviraux
WO2023049829A3 (fr) Peroxydes cycliques utilisés en tant que promédicaments pour l'administration sélective d'agents
FR3084586B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
PT1183247E (pt) Sistemas tiazole policiclicos e sua utilizacao como anorecticos
FR3084585B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
BR112022003751A2 (pt) Análogos de hemoglobina reticulada com tiosuccinila e métodos de uso e preparação dos mesmos
FR3081686B1 (fr) Composition alimentaire comprenant de la phycocyanine

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200207

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6